AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06251999
Drug: fospropofol sedation
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fospropofol sedation for same-day bidirectional endoscopy in elderly patients
Trial: NCT06251999
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: propofol
Trial: NCT05097768
Drug: Dexamethasone 0.5mg
RxNorm normalized name: DEXAMETHASONE 0.5MG TAB
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients will be randomly given the medication by mouth 60 min before administering IANB.
Trial: NCT05241132
Drug: Tislelizumab plus chemotherapy
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Cisplatin: 100mg/m2, injected intravenously every 3 weeks, 8 cycles (period 21 days)~2. Paclitaxel (albumin-bound) : paclitaxel, 175mg/m2, given intravenously every 3 weeks for 8 cycles (period 21 days).~3. Tislelizumab: 200mg, given intravenously every 3 weeks until disease progression or unacceptable toxicity or death or subject withdrawal of informed consent.
Trial: NCT04582305
Drug: Bleomycin
RxNorm normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional bleomycin treatment administered with an electronic pneumatic jet injector
Trial: NCT05754684
Drug: Dinutuximab beta
RxNorm normalized name: dinutuximab beta
DrugBank: Dinutuximab (DB09077)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dinutuximab beta iv for 5 days
Trial: NCT05754684
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-2 sc alternate day for 6 doses
Trial: NCT05754684
Drug: Granulocyte-Macrophage Colony-Stimulating Factor
RxNorm normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte-macrophage colony-stimulating factor sc daily till ANC \>2,000/mm3
Trial: NCT05754684
Drug: Naxitamab
RxNorm normalized name: Naxitamab
DrugBank: Naxitamab (DB15965)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naxitamab iv for 4 days (as alternative for dinutuximab)
Trial: NCT06493136
Drug: lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: questionnaire
Trial: NCT04849377
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 9.0
Trial: NCT04849377
Drug: Cisplatin 200
RxNorm normalized name: CISPLATIN 200MG/VIL (PF) INJ
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg/m2
Trial: NCT04849377
Drug: Cisplatin 240
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 240mg/m2
Trial: NCT05309460
Drug: Labetalol Oral Tablet
RxNorm normalized name: labetalol Oral Tablet
DrugBank: Labetalol (DB00598)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See Labetalol arm.
Trial: NCT05309460
Drug: NIFEdipine ER
RxNorm normalized name: NIFEdipine ER
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See Nifedipine arm.
Trial: NCT05531890
Drug: GTX-102 medium dose fast Period 1 and Period 2
RxNorm normalized name: Fast Freeze
DrugBank: GTX-102 (DB16981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 fast
Trial: NCT05531890
Drug: GTX-102 medium dose slow Period 1 and Period 2
RxNorm normalized name: Slow-Fe
DrugBank: GTX-102 (DB16981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 slow
Trial: NCT05531890
Drug: GTX-102 high dose fast Period 1 and Period 2
RxNorm normalized name: Fast Freeze
DrugBank: GTX-102 (DB16981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) administered in Period 1 and Period 2 fast
Trial: NCT05531890
Drug: GTX-102 low dose fast Period 1 and Period 2
RxNorm normalized name: GTX-102
DrugBank: GTX-102 (DB16981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTX-102 Betamethasone oral spray high dose (0.025 mg/kg) administered in Period 1 and Period 2 fast
Trial: NCT05531890
Drug: Betamethasone solution as intramuscular injection Period 1 and Period 2
RxNorm normalized name: betamethasone Injectable Solution
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: reference product 0.1 mg/kg betamethasone solution as an intramuscular injection
Trial: NCT05531890
Drug: Betamethasone Oral Solution Period 1 and Period 2
RxNorm normalized name: Betamethasone Oral Solution
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparator product 0.1 mg/kg betamethasone oral drops solution
Trial: NCT05727943
Drug: Clioquinol
RxNorm normalized name: Clioquinol
DrugBank: Clioquinol (DB04815)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: add on clioquinol to concomitant ASM
Trial: NCT05549167
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus 0,8 mg/m2, but \<2 mg per day, once a day (QD), per os, oral solution, 1mg/ml, 60 ml Optimal individual dosage of sirolimus will be determined under control of concentration in blood serum. Therapeutic concentration - 5-15 ng/ml. Blood samples will be collected until therapeutic concertation will be achieved in 2 consecutive samples, but no more than 4 samples (on the 4th, 7th, 10th, 14th days of admission).
Trial: NCT05874778
Drug: 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy
RxNorm normalized name: (2R,4'R,8'R)-α-tocopherol
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All enrolled patients will first complete a total of 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy (Rituximab + Cyclophosphamide + Doxorubicin + Prednisolone) and conduct evaluation about treatment effects (i.e. efficacy evaluation) once every 2 cycles, and after their completion of the 6th cycle, they will receive maintenance treatment . After the end of 6th cycle of treatment or after their leaving the group, efficacy evaluation is conducted every three months to obtain relevant data regarding the 2-year Progression-Free Survival(PFS) and survival of the subjects.
Trial: NCT04340908
Drug: Dapagliflozin 10 MG
RxNorm normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg tablet, oral, once daily, 1-year treatment, postoperation
Trial: NCT05376904
Drug: ropivacaine HCl.
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ropivacaine HCl.
Trial: NCT04799847
Drug: Catumaxomab
RxNorm normalized name: catumaxomab
DrugBank: Catumaxomab (DB06607)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study is conducted in 3 phases sequentially: dose escalation phase, dose expansion phase and dose extension phase. In the dose escalation phase, the preliminary safety and pharmacokinetic profile of catumaxomab by instillation, at 2 dose levels(20ug group and 100ug group）, in NMIBC patients are investigated.
Trial: NCT00022893
Drug: Iodine-131 Anti-B1 Antibody
RxNorm normalized name: Iodine-131 anti-b1 antibody
DrugBank: Tositumomab I-131 (DB17991)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05553093
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tirzepatide ih qw
Trial: NCT05553093
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 IU ih qd
Trial: NCT04839055
Drug: Coenzyme A Combined With Abiraterone
DrugBank: Coenzyme A (DB01992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone 4 pieces per day. Coenzyme A 200U
Trial: NCT04839055
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone
Trial: NCT06396416
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Maximum tolerated dose of semaglutide subcutaneously once weekly. Maximum dose of 2.0 mg.
Trial: NCT05701241
Drug: Somatostatin analog
RxNorm normalized name: Somatostatin analog
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin analog treatment every 4 weeks
Trial: NCT04297618
Drug: Xiidra
RxNorm normalized name: Xiidra
DrugBank: Lifitegrast (DB11611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xiidra (lifitegrast 5% ophthalmic solution)
Trial: NCT06376981
Drug: Hyaluronic acid injection
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An injection of 2 ml of Acid hyaluronic
Trial: NCT06625450
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tofacitinib alone will be continued at a dose of 11 mg once a day
Trial: NCT06625450
Drug: Tofacitinib plus mesalamine
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both tofacitinib 11 mg once a day and mesalamine will be continued
Trial: NCT05578430
Drug: Cadonilimab
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/kg by intravenous infusions every 3 weeks
Trial: NCT04161599
Drug: Cefuroxime (750mg) I.V
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extra dosage
Trial: NCT04161599
Drug: Cefuroxime 750mg oral
RxNorm normalized name: cefuroxime 750 MG
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prophylaxis
Trial: NCT04161599
Drug: Metronidazole 250 MG Oral Tablet [Flagyl]
RxNorm normalized name: metronidazole 250 MG Oral Tablet [Flagyl]
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prophylaxis
Trial: NCT04161599
Drug: Metronidazole 1 g Intravenous
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV prophylaxis
Trial: NCT04161599
Drug: Cefuroxime 1,5 g Intravenous
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV prophylaxis
Trial: NCT04716413
Drug: Dsuvia
RxNorm normalized name: Dsuvia
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject will receive up to 2 doses of Dsuvia. The first dose will be intra-op and the second dose will be post-op (if needed)
Trial: NCT05048368
Drug: Larotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, 350 mg, single dose, one day
Trial: NCT02477891
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive daratumumab (16 milligram per kilogram \[mg/kg\]) as intravenous infusion on Day 1, 8, 15, and 22 of Cycles 1 and 2 (weekly dosing), on Day 1 and 15 of Cycles 3 to 6 (every 2 weeks dosing), and on Day 1 of Cycle 7 and subsequent cycles (every 4 weeks dosing) until documented progression, unacceptable toxicity, or study end. Each cycle is of 28 days.
Trial: NCT06319768
Drug: Pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be treated with intralesional PTX (Trentoximal Ampoule 100 mg/5 ml) in a dose of 1mg per lesion at a distance 1cm between two atrophic lesions with a maximum 20 mg per session (with insulin syringe 30Gx8mm). Lesion blanching is the endpoint of injection
Trial: NCT06319768
Drug: platelet rich plasma
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with intralesional PRP. PRP will be obtained by the double-spin method, followed by the collection of 10 mL of autologous whole blood into tubes containing trisodium citrate as an anticoagulant. The collected blood will first be centrifuged at 1000 RPM for 10 minutes at room temperature to separate the red blood cells at the bottom of the tube, the buffy coat (containing the white blood cells) in the middle, and the plasma above (soft spin). Then, the upper plasma will be pipetted above the buffy coat to undergo another centrifugation at 1500 RPM for another10 minutes (hard spin) to obtain a platelet pellet in the bottom of the tube (with a platelet count 4-4.5 times higher than that of baseline) and a platelet-poor plasma(PPP) in the upper part. The PPP will be partly removed and partly used to re-suspend the platelets to finally produce 2 mL of PRP
Trial: NCT06319768
Drug: combined pentoxifylline and platelet rich plasma
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be treated with a combination of both intralesional 1mg of PTX per lesion (with a maximum 20mg per session) then 0.1ml of intralesional PRP at the same lesion after 5 minutes
Trial: NCT05763953
Drug: Etripamil NS
RxNorm normalized name: NS-2359
DrugBank: Etripamil (DB12605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1A: At least 12 patients will be administered with Etripamil NS (35 mg/100 μL per nostril) at a dose of 70 mg.~Part 1B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 1A.~Part 2A: At least 12 patients will be administered with Etripamil NS at a dose selected based on appropriate body size-based modeling using PK assessments, as well as safety/tolerability, and efficacy data collected in Part 1.~Part 2B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 2A.
Trial: NCT05429593
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet given orally
Trial: NCT05429593
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet given orally
Trial: NCT05429593
Drug: Semaglutide/dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet given orally
Trial: NCT06348264
Drug: Rezvilutamide
RxNorm normalized name: Rezvilutamide
DrugBank: Rezvilutamide (DB19133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rezvilutamide 240 mg (3\*80mg tablets) will be administered orally once daily with or without food.
Trial: NCT06348264
Drug: Leuprolide Acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose and frequency of administration will be consistent with the prescribing information in prostate cancer patients.
Trial: NCT03529448
Drug: Temozolomide Oral Product
RxNorm normalized name: temozolomide Oral Product
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During RT, patients will receive Temozolomide (TMZ). All patients will be given TMZ at 75 mg/m2/d concurrently with RT for a maximum of 42 days.~At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles.
Trial: NCT05246072
Drug: Ivermectin + colchicine
RxNorm normalized name: Colchicine
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In addition to the local standard of care for COVID 19 patients, the patient will receive Ivermectin + colchicine
Trial: NCT05246072
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In addition to the local standard of care for COVID 19 patients, the patient will receive colchicine
Trial: NCT06099951
Drug: Serplulimab + FOLFOXIRI
RxNorm normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting from day 0, the patient will receive 8 cycles of FOLFOXIRI regimen at specific intervals. The FOLFOXIRI regimen includes irinotecan 165mg/m2, oxaliplatin 85mg/m2, calcium folinate 200mg/m2 on day 1, followed by continuous intravenous infusion of 5-FU 2400mg/m2/day for 46 hours. This regimen is repeated every 14 days.During radiotherapy (Monday to Friday), the patient will receive capecitabine 1650mg/m2/day orally twice daily. Serplulimab immunotherapy will be administered every 2 weeks during the FOLFOXIRI neoadjuvant chemotherapy period. Serplulimab will be given on the first day and the 14th day of radiotherapy, dissolved in 100ml normal saline and administered intravenously over 30-60 minutes at a dose of 200mg.
Trial: NCT05221138
Drug: VV116
RxNorm normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: VV116 oral tablets, 400mg
Trial: NCT04428008
Drug: Thymalfasin
RxNorm normalized name: Thymalfasin
DrugBank: Thymalfasin (DB04900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic 28 amino acid peptide
Trial: NCT06468670
Drug: sintilimab，programmed death 1 monoclonal antibody
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: short-course radiotherapy~+sintilimab (200mg, iv, D1, Q3W)
Trial: NCT05799469
Drug: Envafolimab
RxNorm normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC
Trial: NCT05799469
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05730114
Drug: Antiplatelet Drug
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-P2Y12 oral agent administered during primary percutaneous coronary intervention.
Trial: NCT04665609
Drug: Anlotinib and TQB2450 solution
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib is a novel multitarget tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling. TQB2450 solution is a new novel of PD-L1 inhibitor made by Crown Bioscience and CHIATAI TIANQING(CTTQ PHARMA).
Trial: NCT05525247
Drug: SLC-3010
RxNorm normalized name: SLC-391
DrugBank: SLC-391 (DB18814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion over 30 minutes on day 1 of each 21-day cycle
Trial: NCT04629443
Drug: S 64315 (also referred as MIK665) and azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) administered via intravenous (IV) infusion over at least 2 hours.~During the combination treatment period S64315 will be administered according to a dose escalation scheme starting at 50 mg up to 250 mg might be explored. The schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen of azacitidine administered at 75 mg/m² via subcutaneous (SC) injection for 7 days from D1 to D7 of each cycle followed by a rest period of 21 days.
Trial: NCT06008223
Drug: vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Patients in experimental group were given vitamin B6 injection 300mg/d (100mg/2ml× 3) intravenous injection.
Trial: NCT06008223
Drug: 0.9% sodium chloride solution
RxNorm normalized name: Precedex 80mcg/20mL in 0.9% Sodium Chloride Solution for Injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: That in control group were injected with 0.9% sodium chloride solution 6 ml intravenously.
Trial: NCT05034536
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT05034536
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT05034536
Drug: Relatlimab
RxNorm normalized name: Relatlimab
DrugBank: Relatlimab (DB14851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT05034536
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT05616598
Drug: Sofosbuvir +daclatasvir+ simeprevir+Ribavirin
RxNorm normalized name: Simeprevir
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral daily dose of Sofosbuvir +daclatasvir + simeprevir+ Ribavirin for 3 months
Trial: NCT05573581
Drug: Botox
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botulinum toxin type A will be first injected into anterior belly of digastric muscles 2-3 days prior to any surgical intervention (for the BTX to be clinically effective)(Sadick and Matarasso 2004). A total of 20 U of Botox will be injected bilaterally by using 25g needle, 1 cc insulin syringe through extraoral approach in 4 point
Trial: NCT06487143
Drug: Triptorelin pamoate（15mg）
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triptorelin pamoate 15mg is administered via intramuscular injection once every three months.
Trial: NCT06487143
Drug: Triptorelin acetate （3.75mg）
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triptorelin acetate 3.75mg is administered via intramuscular injection once every four weeks.
Trial: NCT01233570
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily application for 12 weeks followed by 4 weeks observation. Optional 36 week open label extension
Trial: NCT04965116
Drug: Progestin Only Contraceptive Pills
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily pill (placebo or active tablet)